FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Insights - Beijing Meisen Pharmaceutical announced the approval of the world's first topical treatment for proliferative superficial infantile hemangiomas, Timolol Maleate Gel, by the National Medical Products Administration (NMPA) on September 30, 2025 [1][2] - The successful launch of Timolol Maleate Gel demonstrates China's capability to transition from imitation to original innovation in the pharmaceutical industry [2] Group 1: Product Development and Approval - Timolol Maleate Gel is designed for the treatment of proliferative superficial infantile hemangiomas, a common pediatric skin condition that can lead to serious complications if not treated early [1] - The gel was developed by Beijing Meisen Pharmaceutical, which conducted a systematic pharmacokinetic study of Timolol in infants aged 28 to 180 days, marking a first in the international arena [1] Group 2: Market Research and Support - Yidu Technology's project consulting and evaluation team provided critical market research and project analysis services, supporting the drug's development and market entry [1] - The team was involved from the early feasibility study to later clinical strategies, ensuring that each step of the project was based on reliable information [1] Group 3: Industry Impact and Collaboration - Yidu Technology has served over 350 pharmaceutical companies, supporting 686 clinical trials and 275 real-world studies, facilitating the approval of multiple innovative drugs [2] - The collaboration between Yidu Technology and Beijing Meisen Pharmaceutical represents a significant milestone in advancing pediatric drug development [2]

Core Viewpoint - The company, Yidu Tech, has conducted share buybacks in Hong Kong, indicating a strategy to enhance shareholder value amidst fluctuating stock prices [2] Summary by Category Share Buyback Details - On October 13, Yidu Tech repurchased 1.0308 million shares at prices ranging from 5.800 HKD to 5.990 HKD, totaling 6.092 million HKD [2] - The stock closed at 6.000 HKD on the same day, reflecting a decrease of 2.60% with a total trading volume of 101 million HKD [2] - Year-to-date, the company has completed three buybacks, accumulating a total of 1.7188 million shares repurchased and a total expenditure of 10.0183 million HKD [2] Buyback Breakdown - Buyback details include: - October 13: 1.0308 million shares at a maximum price of 5.990 HKD and a minimum price of 5.800 HKD, costing 6.092 million HKD [2] - September 29: 0.3350 million shares at a maximum price of 5.790 HKD and a minimum price of 5.670 HKD, costing 1.9271 million HKD [2] - September 26: 0.3530 million shares at a maximum price of 5.690 HKD and a minimum price of 5.570 HKD, costing 1.9992 million HKD [2]

智通财经APP讯，医渡科技(02158)发布公告，该公司于2025年10月13日斥资609.2万港元回购103.08万股 股份，每股回购价格为5.8-5.99港元。 ...

Core Viewpoint - The company, Yidu Tech (02158), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will spend HKD 6.092 million to repurchase 1.0308 million shares [1] - The buyback price per share ranges from HKD 5.80 to HKD 5.99 [1]

Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on October 13, 2023, spending HKD 6.092 million to repurchase 1.0308 million shares at a price range of HKD 5.80 to HKD 5.99 per share [1] Summary by Category Company Actions - Yidu Tech executed a buyback of 1.0308 million shares at a total cost of HKD 6.092 million [1] - The repurchase price per share ranged from HKD 5.80 to HKD 5.99 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月13日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年9月30日 | 1,067,049,081 | | 3,579,100 | | 1,070,628,181 | | 1) ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 醫渡科技有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 ...

Core Points - Yidu Tech (02158) shares rose over 6%, currently up 6.27% at HKD 7.12, with a trading volume of HKD 112 million [1] - The company announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately RMB 55.82 million [1] - At the "First Medical Artificial Intelligence Conference and Health Industry AI Application and Development Exhibition" held in Jinan, Dr. Li Linfeng, Vice President of Technology Innovation and AI Architect at Yidu Tech, introduced the "Doctor Copilot" built on the foundation of "big data + Yidu domain-specific large model," which has been implemented in several hospitals to enhance diagnostic efficiency and quality, aiding in the intelligent and standardized upgrade of clinical practices [1] Summary by Categories Financial Performance - Yidu Tech's stock price increased by 6.27%, reaching HKD 7.12, with a trading volume of HKD 112 million [1] Project Development - The company secured a project worth approximately RMB 55.82 million for the Phase III clinical research of SMR001 eye drops [1] Technological Innovation - The "Doctor Copilot" technology, which integrates clinical workflows, has been successfully implemented in multiple hospitals, improving diagnostic efficiency and quality [1]

消息面上，医渡科技公布，近期，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限 公司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。此 外，由《中国卫生信息管理杂志》社主办的"首届医学人工智能大会暨卫生健康行业AI应用与产业发展 展览会"近日于济南举办。在大会"AI驱动医疗质量提升"论坛上，医渡科技技术创新副总裁、AI架构师 李林峰博士介绍，医渡科技以"大数据+医渡垂域大模型"为技术底座，构建了深度融合临床工作流的"医 生Copilot"。目前，医生Copilot已在多家医院落地应用，有效提升诊疗效率与质量，助力临床实现智能 化、规范化升级。 智通财经APP获悉，医渡科技(02158)涨超6%，截至发稿，涨6.27%，报7.12港元，成交额1.12亿港元。 ...